Altria Group, Inc. (MO) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed but overall positive picture. Strong financial metrics include an increase in oral tobacco margins and cigarette retail share. Despite a decline in shipment volume, the growth in the on! product line and increased retail share are positives. The Q&A reveals confidence in future performance and strategic initiatives like international expansion and product differentiation. Although there are concerns about deceleration in earnings growth and competitive pressures, the raised EPS guidance and share repurchase plan are positive signals. Given these factors, a positive stock price movement is likely.
Key Financial Performance
Adjusted diluted earnings per share (EPS) Increased by 3.6% in the third quarter and by 5.9% for the first 9 months year-over-year. Reasons for the increase include strong financial performance and progress in the smoke-free portfolio.
Smokeable products segment adjusted operating company's income (OCI) Grew by 0.7% to nearly $3 billion in the third quarter and by 2.5% to $8.4 billion for the first 9 months year-over-year. Reasons include focus on maximizing profitability and strategic investments in the discount segment.
Smokeable products segment adjusted OCI margins Expanded to 64.4% for the third quarter and first 9 months, representing margin growth of 1.3 percentage points and 2.7 percentage points year-over-year. Reasons include effective cost management and profitability strategies.
Domestic cigarette volumes Declined by 8.2% in the third quarter and 10.6% for the first 9 months year-over-year. Adjusted for trade inventory movements and calendar differences, the decline was 9% for the third quarter and 10.5% for the first 9 months. Reasons include macroeconomic headwinds and consumer spending pressures.
Oral Tobacco Products segment adjusted OCI Declined by less than 1% in the third quarter but increased by 3.3% for the first 9 months year-over-year. Reasons include growth in on! nicotine pouches offset by lower moist smokeless tobacco (MST) volumes.
Oral Tobacco Products segment adjusted OCI margins Expanded by 2.4 percentage points to 69.2% in the third quarter and by 1.8 percentage points to 69% for the first 9 months year-over-year. Reasons include improved profitability and growth in the on! product line.
Oral Tobacco Products segment reported shipment volume Decreased by 9.6% in the third quarter and 5.2% for the first 9 months year-over-year. Adjusted for calendar differences and trade inventory movements, the decline was 5.5% for the third quarter and 3.5% for the first 9 months. Reasons include lower MST volumes despite growth in on! nicotine pouches.
Cigarette retail share Increased sequentially for the second consecutive quarter to 45.4%, growing 0.3 share points in the third quarter year-over-year. Reasons include strategic investments in the discount segment and Marlboro's leadership in the premium segment.
Helix's on! reported shipment volume Grew to over 42 million cans in the third quarter, an increase of nearly 1% year-over-year. For the first 9 months, it grew to over 133 million cans, an increase of approximately 15% year-over-year. Reasons include steady consumer demand and promotional activities in the nicotine pouch category.
Helix's on! retail share of the total oral tobacco category Was 8.7% for the third quarter and first 9 months, demonstrating stability for the quarter and an increase of 0.8 share points for the first 9 months year-over-year. Reasons include steady consumer demand and competitive pricing.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
on! PLUS launch: Helix launched on! PLUS, a next-generation oral nicotine product, in Florida, North Carolina, and Texas. It features three flavors and three nicotine strengths, aiming to appeal to both adults who dip and competitive nicotine pouch consumers.
Heated tobacco products: Horizon filed regulatory applications with the FDA for Ploom and Marlboro heated tobacco sticks, marking progress in bringing these products to the U.S. market.
E-vapor product development: NJOY completed the design of a modified ACE product to address patent disputes and is evaluating pathways to market it.
International nicotine pouch expansion: Altria announced a collaboration with KT&G to explore global demand for nicotine pouch products, including potential international expansion of the on! portfolio.
Non-nicotine product exploration: Altria and KT&G are exploring opportunities in the U.S. non-nicotine market, particularly in the energy and wellness space.
Regulatory progress: The FDA launched a pilot program to streamline reviews for oral nicotine pouches, including on! PLUS, signaling potential acceleration in regulatory decisions.
Enforcement actions: Federal agencies seized over 4 million illicit vapor products worth $86 million, indicating progress in regulatory enforcement.
Collaboration with KT&G: Altria entered into a collaboration with KT&G to enhance operational efficiency in traditional tobacco and explore joint opportunities in nicotine and non-nicotine products.
Shareholder returns: Altria increased its quarterly dividend by 3.9% and expanded its share repurchase program from $1 billion to $2 billion, emphasizing its commitment to shareholder value.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Competitive pressures in nicotine pouch market: Highly elevated competitor promotional activity, particularly in September, driving incremental growth for nicotine pouches and influencing long-term brand adoption.
Regulatory hurdles for smoke-free products: FDA's slow pace in market authorizations for smoke-free products and the need for sustained enforcement against illicit vapor products.
Litigation risks in e-vapor business: Ongoing litigation between NJOY and JUUL over patent infringement claims, with potential delays in product launches and financial implications.
Economic pressures on tobacco consumers: Macroeconomic headwinds, including inflation, affecting discretionary spending and shifting consumer behavior towards discount segments.
Declining cigarette volumes: Reported domestic cigarette volumes declined by 8.2% in the third quarter and 10.6% for the first 9 months, reflecting broader industry trends.
Illicit vapor product market: Saturation of the market with flavored disposable e-vapor products, many of which have evaded regulatory processes, representing over 60% of the category.
Supply chain and inventory dynamics: Trade inventory dynamics influenced shipment volumes for nicotine pouches, impacting quarterly performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Adjusted Diluted EPS Guidance: Altria raised the lower end of its 2025 adjusted diluted EPS guidance range to $5.37 to $5.45, representing a growth rate of 3.5% to 5% from a base of $5.19 in 2024. EPS growth is expected to moderate in the fourth quarter due to factors such as the lower share count from the 2024 accelerated share repurchase program and the expiration of the MSA legal fund.
Nicotine Pouch Market Trends: Oral nicotine pouches are driving a 14.5% increase in oral tobacco industry volume over the past 6 months. Helix's on! PLUS product is expected to appeal to both adults who dip and competitive nicotine pouch consumers, with plans to expand flavors and nicotine strengths.
Heated Tobacco Products: Horizon filed a combined PMTA and MRTPA with the FDA for Ploom and Marlboro heated tobacco sticks. The company is working on go-to-market plans for Ploom and expects FDA authorizations to support its launch.
E-Vapor Business: Altria is evaluating pathways to bring a modified NJOY ACE product to market, addressing patent disputes. The e-vapor market remains saturated with flavored disposable products, but enforcement actions and regulatory dialogue are expected to improve market conditions.
Regulatory Developments: The FDA launched a pilot program to streamline PMTA reviews for oral nicotine pouches, including Helix's on! PLUS applications. Altria is encouraged by this development and hopes it signals broader FDA efforts to accelerate regulatory decisions across smoke-free platforms.
International Expansion and Collaboration: Altria announced a collaboration with KT&G to explore global demand for nicotine pouch products and U.S. non-nicotine products. This includes potential expansion of the on! portfolio into international markets and investment in Another Snus Factory, the manufacturer of the LOOP Nicotine Pouch brand.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Increase: In August, Altria announced its 60th dividend increase in 56 years, raising the regular quarterly dividend by 3.9% to $1.06 per share.
Dividend Payments: For the first 9 months of 2025, Altria returned $5.2 billion to shareholders through dividends.
Share Repurchase Program Expansion: Altria's Board authorized an expansion of the existing share repurchase program from $1 billion to $2 billion, with the program now expiring on December 31, 2026.
Share Repurchases: In the first 9 months of 2025, Altria repurchased $712 million worth of shares.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Sal, you raised the low end of the guidance again, but the fourth quarter implies a deceleration in earnings growth. Are there any other key factors to consider for the fourth quarter and the path to growing smokeable OCI again?
A:Salvatore Mancuso mentioned that apart from the share repurchase and MSA legal funnel, they are monitoring consumer spending and the dynamic marketplace. He expressed confidence in PM USA's performance and their ability to expand margins for Marlboro in the premium segment.
Q:What are the drivers behind the moderation in the underlying cigarette industry rate of decline on a sequential basis?
A:William Gifford attributed the moderation to consistency in gas prices and inflation, as well as stepped-up enforcement in e-vapor, which puts consumers back at play and leads them to consider other nicotine categories.
Q:Could you touch on the competitive environment in the nicotine pouch category and share early feedback on the rollout of on! PLUS?
A:William Gifford noted intensified competition, with on! moving up 1.5% in retail price while the category declined significantly. He highlighted steady retail takeaway volume despite competition. On! PLUS is still in early stages, and they are excited about its differentiation and potential for expansion.
Q:Could you provide more color on the KT&G partnership, including operational efficiencies, alternative revenue streams, and international expansion opportunities?
A:William Gifford outlined three aspects: expanding on! and on! PLUS internationally, exploring non-nicotine opportunities like Korean red ginseng, and adapting manufacturing for international markets to benefit from duty drawbacks and explore future international opportunities.
Q:Could you discuss the pricing strategy for on! PLUS and the factors behind the muted smokeable OCI growth in the quarter?
A:William Gifford stated that on! PLUS is positioned as a premium product with introductory price promotions. Salvatore Mancuso explained that controllable costs should be viewed long-term, emphasizing cost management and reinvestment through the Optimize and Accelerate program. Smokeable OCI growth was 2.5% year-to-date, reflecting Marlboro's strength in the premium segment.
Q:Should the federal excise tax payments be considered a key driver for EPS growth, and how does the FDA pilot program impact the national launch of on! PLUS?
A:William Gifford advised against jumping to conclusions about excise tax payments as a key driver. He emphasized making decisions based on long-term interests and highlighted the FDA's collaborative approach in the pilot program for nicotine pouches, which could eventually expand to other categories.
Q:Could you clarify if EPS growth is expected to accelerate to high single digits to meet the mid-single-digit EPS CAGR by 2028?
A:William Gifford confirmed that their ambition remains aligned with the previously stated mid-single-digit EPS CAGR goal.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the potential benefit of duty drawbacks and the exact timeline or strategy for the national rollout of on! PLUS. Additionally, they did not provide clarity on the controllable costs for smokeables in the future or the exact impact of the FDA pilot program on their decisions.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACE product
FDA product
Helix shipment
Horizon
JUUL litigation
NJOY JUUL
PLUS
Ploom
adult consumer
application
brand sample
can increase
capability
claim patent
collaboration
commitment
consumer preference
demand
enforcement effort
enterprise goal
expansion
flavor
harm reduction
infringement sale
litigation JUUL
opportunity
oral
patent infringement
pathway
pilot
progress enforcement
relationship KTG
research
science
seizure
smoke portfolio
smoke product
speed
stability
MO Transcript
Altria Group, Inc. (MO) Q1 2026 Earnings Call Transcript
Positive4-30
The earnings call indicates solid financial performance with revenue, operating income, and EPS all showing year-over-year growth. The gross margin improvement and increased cash flow from operations further highlight operational efficiency. Although strategic initiatives were not discussed, the financial metrics and share repurchases suggest a positive outlook. However, the lack of clarity on future dividends introduces some uncertainty. Overall, the financial strength and market strategies suggest a positive sentiment, likely resulting in a stock price increase of 2% to 8% over the next two weeks.
Altria Group, Inc. (MO) Presents at Consumer Analyst Group of New York Conference 2026 Transcript
Neutral2-18
Altria Group, Inc. (MO) Q4 2025 Earnings Call Transcript
Positive1-29
The earnings call highlights strong financial performance with increased EPS guidance, substantial dividends, and share repurchases. The nicotine pouch market is expanding, and new product developments are underway, supported by regulatory advances. The Q&A section reveals strategic investments in manufacturing and import-export, despite some cost increases. Analysts appear positive, with concerns addressed by management's focus on growth and shareholder returns. Overall, the company's initiatives and optimistic guidance suggest a positive outlook for the stock.
Altria Group, Inc. (MO) Q3 2025 Earnings Call Transcript
Positive10-30
The earnings call presents a mixed but overall positive picture. Strong financial metrics include an increase in oral tobacco margins and cigarette retail share. Despite a decline in shipment volume, the growth in the on! product line and increased retail share are positives. The Q&A reveals confidence in future performance and strategic initiatives like international expansion and product differentiation. Although there are concerns about deceleration in earnings growth and competitive pressures, the raised EPS guidance and share repurchase plan are positive signals. Given these factors, a positive stock price movement is likely.
MO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
